Related Experiment Video

Updated: May 11, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Targeted therapy with kinase inhibitors in aggressive endocrine tumors

Vincenzo Marotta1, Maria Domenica Franzese, Michela Del Prete

  • 1Federico II University, Department of Clinical Medicine and Surgery, Italy. vinc.endo@libero.it

Expert Opinion on Pharmacotherapy
|May 17, 2013
PubMed
Abstract

Insights

Kinase inhibitors (KIs) show promise in controlling advanced endocrine cancers, improving progression-free survival. However, they do not cure the disease, necessitating research into synergistic therapies and tumor genotyping for combined treatments.

Area of Science:

  • Oncology
  • Pharmacology
  • Genetics

Background:

  • Kinase inhibitors (KIs) target protein kinases, crucial in cell processes and oncogenesis.
  • KIs are increasingly used for advanced endocrine cancers resistant to chemotherapy.

Purpose of the Study:

  • To review genetic alterations in endocrine tumors and the rationale for KI use.
  • To analyze clinical trials on KIs in aggressive endocrine cancer.
  • To discuss KI adverse effects and their mechanisms.

Main Methods:

  • Literature review of PubMed Central clinical trials.
  • Summary of genetic alterations in endocrine tumors.
  • Analysis of KI efficacy, adverse effects, and resistance mechanisms.

Main Results:

  • KIs achieve radiological disease control and improve progression-free survival in endocrine cancers.
  • Mechanisms of adaptation can circumvent KI molecular blockade, preventing a cure.
  • Identifying synergistic agents and comprehensive tumor genotyping are key for future treatments.

Conclusions:

  • KIs offer significant benefits but not a cure for endocrine cancers.
  • Future strategies involve combining KIs with other agents to overcome resistance.
  • Personalized medicine through tumor genotyping will guide combined targeted therapies.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...